Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease

This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Inclusion Criteria:

• Age>18 years
• Written informed consent
• Glomerular Filtration Rate (GFR)≥ 30 ml/min/1.73m2 [CKD stage G1-G3]
• Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients

Exclusion Criteria:

• Active malignancy
• Class I or equivalent indication for treatment with a SGLT2 inhibitor
• Pregnancy or willing of pregnancy during the follow up period
• Active urogenital infection
• Diabetes mellitus type 1
• History of diabetic ketoacidosis
• Cardiogenic shock
• eGFR < 29 ml/min/1.73m2